1
Approved , Date: 5 September 2018Janssen Scientific Affairs *
Statistical Analysis Plan
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory 
Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous 
Thromboembolism
Protocol STM4001; Phase [3b]
BAY59 -7939/JNJ39039039STM4001 (Rivaroxaban)
Status: Approved
Date: 5 September 2018
Prepared by: [CONTACT_12945] & Development, LLC
Document No.: EDM S-ERI-120534500; 6.0
Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP) . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
2
Approved , Date: 5 September 2018TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
AMENDMENT HISTORY .............................................................................................................................. 4
ABBREVIA TIONS ........................................................................................................................................ 7
1. INTRODUCTION .................................................................................................................................. 8
1.1. Study Objectives .............................................................................................................................. 8
1.2. Study Design .................................................................................................................................... 9
1.2.1. Study Drug Discontinuation and Early W ithdrawal from Double- Blind Period ........................... 10
1.3. Statistica l Hypotheses for Study Objectives .................................................................................. 10
1.4. Sample Size Justification ............................................................................................................... 10
1.5. Randomization and Blinding .......................................................................................................... 12
2. GENER AL ANALYSIS DEF INITIONS .............................................................................................. 13
2.1. Visit Windows ................................................................................................................................ .13
2.2. Baseline ......................................................................................................................................... 13
2.3. Pooling Algorithm for Analysis Centers .......................................................................................... 13
2.4. Analysis Populations ...................................................................................................................... 13
2.4.1. Intent -to-Treat (ITT) Population .................................................................................................. 13
2.4.2. Per-Protocol (PP) Population ..................................................................................................... 13
2.4.3. Safety Population: ....................................................................................................................... [ADDRESS_569149] Dose Observation Period ........................................................................................... 19
2.7. Definition of Subgroups .................................................................................................................. 20
3. INTERIM A NALYSIS A NDINDEPENDENT DA TA MON ITORING COMMITTEE (I DMC) .............. [ADDRESS_569150] INFORM ATION................................................................................................................ 21
4.1. Demographics and Baseline Characteristics ................................................................................. 21
4.2. Disposition Information ................................................................................................................... 21
4.3. Treatment Compliance Based on Exposure .................................................................................. 21
4.4. Extent of Exposure ......................................................................................................................... 22
4.5. Systemic Cancer Therapi[INVESTIGATOR_447392] .......................................................... 22
4.6. Study Drug Discontinuation and Early W ithdrawal from Double- Blind Period ............................... 22
5. EFFIC ACY ......................................................................................................................................... 24
5.1. Analysis Specifications ................................................................................................................... 24
5.1.1. Level of Significance ................................................................................................................... 24
5.1.2. Data Handling Rules ................................................................................................................... 24
5.2. Primary Efficacy  Composite Endpoint ............................................................................................ 24
5.2.1. Definition ..................................................................................................................................... 25
5.2.2. Analysis Methods ........................................................................................................................ 25
[IP_ADDRESS]. Assessment of Proportional Hazards Assumption .................................................................. 25
5.2.3. Supportive Analyses for Primary  Efficacy  Composite Endpoint ................................................. 25
5.2.4. Subgroup Analyses fo r the Primary  Efficacy  Composite Endpoint ............................................. 26
5.2.5. Sensitivity Analy ses.................................................................................................................... 27
[IP_ADDRESS]. Additional Primary  Efficacy  Composite Endpoint –Include As ymptomatic Distal DVT .......... 27
[IP_ADDRESS]. Sensitivity Analy sis for Primary Efficacy  Composite En dpoint ................................................ 27
5.3. Competing Risk Analysis ............................................................................................................... 28
5.4. Key Secondary Endpoints .............................................................................................................. 29
5.4.1. Definition ..................................................................................................................................... 29
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
3
Approved , Date: 5 September [ZIP_CODE].4.2. Analysis Methods ........................................................................................................................ 29
5.5. Adjustment for Multiplicity .............................................................................................................. 30
5.6. Additional Secondar y Efficacy  Variab le(s)..................................................................................... 30
5.6.1. Definition ..................................................................................................................................... 31
5.6.2. Analysis Methods ........................................................................................................................ 32
5.7. End-of-Study Vital Status Summary .............................................................................................. 32
6. SAFETY ............................................................................................................................................. 33
6.1. Bleeding ......................................................................................................................................... 33
6.1.1. Bleeding Events Classification ................................................................................................... 33
6.1.2. Primary Safety Endpoint of Bleeding .......................................................................................... 34
[IP_ADDRESS]. Definition .................................................................................................................................. 34
[IP_ADDRESS]. Analysis Methods .................................................................................................................... 34
6.1.3. Supportive Analysis of the Pri mary Safety Endpoint of Bleeding ............................................... 35
6.1.4. Secondary Safety Endpoints of Bleeding ................................................................................... 35
[IP_ADDRESS]. Definition .................................................................................................................................. 35
[IP_ADDRESS]. Analysis Methods .................................................................................................................... 35
6.2. Adverse Events .............................................................................................................................. 36
6.2.1. Imputation Rules for Missing AE Dates ...................................................................................... 37
6.2.2. Adverse Events Resulting in Withdrawal from the Study and Di scontinuation of 
Treatment: .................................................................................................................................. 37
6.2.3. Serious Adverse Events (SAE) and Deaths during the Study: ................................................... [ADDRESS_569151] ............................................................................................. 38
6.3. Clinical Laboratory Tests ................................................................................................................ 39
6.4. Vital Signs and Phy sical Examination Findings ............................................................................. 39
6.5. Electr ocardiogram .......................................................................................................................... 39
6.6. Other Safety Parameters ............................................................................................................... 39
7. PHARM ACOKINETICS/PHA RMACODYN AMICS........................................................................... 39
7.1. Pharmacokinetics ........................................................................................................................... 39
7.2. Pharmacodynamics ........................................................................................................................ 39
8. BIOM ARKER ..................................................................................................................................... 40
9. HEA LTH CA RE RESOURCE UTILIZA TION .................................................................................... 40
REFERENCES ............................................................................................................................................ 41
ATTACHMENT: EXA MPLES OBSERVA TION PERIOD A ND EVENT/CENSORING T IME.................... 42
ATTACHMENT: IDMC DAT A PRESENT ATION SPECIFICA TION .......................................................... 46
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
4
Approved , Date: 5 September 2018AMENDMENT HISTORY
All changes and clarifications of planned anal yses in the SAP are listed below:
Topic or Section Description of Cha nges and Clarifications of Planned Analyses
Changes from v 5.0 to v6 .0
2.5
Definition of Study DatesImputation rule for partial exposure end dates was added to the rule of 
missing end dates.
Changes from v 4.0 to v5.0
2.5
Definition of Study Dates and
Observation Period End DatesUp-to-Day 180 observation period end date for subjects who withdrew 
early is maximum of withdrawal date and randomization date+180 days.
2.6
Subgroups Subgroup criteria for the Khorana score is update to 2, 3, 4, and ≥5.
4.[ADDRESS_569152] 30 total 
randomized subjects in each subgroup category
5.6, 5.6.1
Additional Secondary Efficacy 
Variables
Defin itionA 3rdcomposite endpoint is added to the secondary efficacy endpoints.  
This is a composite of events in the prim ary efficacy composite endpoint, 
fatal/non -fatal ATE, and visceral VTE .
A 4thcomposite endpoint is added to the secondary efficacy endpoints.  
This is a composite of symptomatic VTE events and major bleeding
9
Health Care Resource UtilizationSection heading relabeled and only descriptive statistics (frequency counts, 
mean, median, SD) will be pr esented.
Attachment Added IDMC Data Preparation Specification .
Version 3.0 to 4.0 Document resaved with no changes made to v3.0
Changes from v2.0 to 3.0
1.0
IntroductionUpdated the version of the protocol to Amendment INT-4 finalized on 
February 16, 2018. 
1.1
Study Objectives/Primary ObjectiveThe occurrence of symptomatic lower extremity distal DVT event is 
included in the primary objective based on the amended protocol (v4.0).
1.3
Statistical Hypothesis for Study 
ObjectiveThe occurrence of symptomatic lower extremity distal DVT event is 
included in the composite.
1.4 
Sample Size JustificationSection updated based on the amended protoco l (v 4.0). The following text 
is added –Towards the end of the enrollment phase, approximately [ADDRESS_569153] assessment date during 
the study, including the Day 210/Post -Treatment Follow -Up visit .
5.2 
Primary Efficacy Composite Endpoint
5.2.1 
DefinitionThe occurrence of symptomatic lower extremity distal DVT event is 
included in the primary efficacy composite endpoint.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
5
Approved , Date: 5 September [ZIP_CODE].2.4
Subgroup Analyses for the Primary 
EndpointSubgroup analysis will be performed if there are enough subjects in each 
subgroup (at least 5% of total randomized subjects).  In addition, the Gail-
Simon test is specified to assess interactions if found to be significant.
5.[ADDRESS_569154] occu rrence of fatal/non -fatal ATE i s defined .
Additional composite endpoint of symptomatic events and major bleeding 
event i s added.
6.1.[ADDRESS_569155] permanently discontinuing study drug.
2.3.1
Intent -to-Treat (ITT) Population
2.3.3 Per -Protocol (PP) PopulationSection numbering corrected.
2.3.[ADDRESS_569156] Dose Observation PeriodImputation rule using a conservative approach for random ized subjects but 
never dosed i s added.
2.6
Definition of SubgroupsTumor type subgroup i s clarified.
4.3
Treatment ComplianceImputation rule in the event of missing inform ation on the returned number 
of tables added.
4.6
Study Discontinuation and Early 
Withdraw al from Double -Blind PeriodSection updated to include two scenarios with regards to discontinuation 
from study treatment and withdraw al from double -blind period.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
6
Approved , Date: 5 September [ZIP_CODE].1.2
Data Handling RulesImputation rule for partial dates is added.
5.2.2
Analysis MethodsThe primary composite endpoint analysis will be based on the Up-to-Day 
180 observation period for the ITT population
[IP_ADDRESS]
Assessment of Proportional Hazards 
AssumptionIn event of non -proportional hazards, alternative approaches were included.
5.2.3 
Supportive Analyses for Primary 
Efficacy Composite EndpointSection updated to include supportive analysis based on the on-treatment 
observation period.
[IP_ADDRESS]
Additional Primary Efficacy 
Com posite Endpoint –Include Distal 
DVTAdditional composite efficacy endpoint defined to include the occurrences 
of symptomatic lower extremity distal DVT and asymptomatic lower 
extremity distal DVT.
[IP_ADDRESS]
Sensitivity Analysis for Primary 
Efficacy EndpointClarification for analysis i s added. 
5.3
Com peting Risk AnalysisSection moved from 5.6. 
5.4.2
Analysis MethodsAnalysis of key secondary efficacy endpoints will be based on the up-to-
day 180 observation period.
6.1.3
Supportive Analysis of the Primary 
Safety Endpo int of BleedingAdditional supportive analysis of time to multiple bleeding event using 
recurrent event analysis i s added.
Attachments Illustrations with examples depi[INVESTIGATOR_447393] i s added
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
7
Approved , Date: [ADDRESS_569157] ratio
IDMC Independent Data Monitoring Committee
ISTH International Society on Thrombosis & Haemostasis
ITT Intent -to-treat
MedDRA Medical Dictionary for Regulatory Activities
PD pharmacodynamic
PE pulmonary embolism
PK pharmacokinetic(s)
PP per-protocol
RRR relative risk reduction
SAE serious adverse event
SAP Statistical Analysis Plan
SD standard deviation
T&E Time and Events
TEAE treatment -emergent adverse event
VTE venous thromboembolism
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
8
Approved , Date: 5 September [ZIP_CODE]. INTRODUCTION
This statistical analy sis plan (SAP) specifies definitions of anal ysis populations , derived variables, 
and statistical methods for analy sis of efficacy and safet y for the Phase 3b study  BAY59 -
7939/ JNJ39039039 STM4001 . This SAP is based on the Clinical Protocol BAY59 -
7939/ JNJ39039039 STM4001 Amendment INT -4finalized on February  16, 201 8. 
Titles, mock- ups and programming instructions for all statistical outputs (tables, figures, and 
listings) will be provided in a separate document entitled Data Presentation Specifications (DPS).
This study SAP will be finalized prior to database lock.  
This study  SAP isalso used for the Independent Data Monitoring Committee (IDMC) pre-
specified safet y revie ws.  For the IDMC however the definition s and imputation rules are defined 
based on the data cutoff sand accumulating data at the time of each DMC meetings .  
1.1. Study Objectives
Primary Objective
The primary  efficacy  objective is to demonstrate that rivaroxaban is superior to placebo for 
reducing the risk of the primary composite outcome as defined by [CONTACT_447401], asymptomatic lower extremity  proximal DVT, 
symptomatic lower extremity  distal DVT, symptomatic upper extremity  DVT, symptomatic non-
fatal PE, incidental PE, and VTE-related deaths in ambulatory  adult subjects with various cancer 
types receiving s ystemic cancer therapy  who are at high risk of developi[INVESTIGATOR_007] a VTE.
Secondary Objectives
The key secondary  efficacy  objectives of this study  are to compare the efficacy  of rivaroxaban 
with placebo for reducing the risk of symptomatic VTE events and VTE related deaths and all-
cause mortality  in ambulatory  adult subjects with various cancer types receiving systemic cancer 
therap y who are at high risk of developi[INVESTIGATOR_007] a VTE.
Other secondary  efficacy  objectives include the evaluation of the individual components of the 
primary  efficacy  composite outcome variable, confirmed fatal/non- fatal arterial thromboembolism 
(ATE) events, confirmed fatal/non -fatal visceral VTE events, symptomat ic lower extremity  distal 
DVT, a composite of s ymptomatic lower extremity  proximal DVT, as ymptomatic lower extremit y 
proximal DVT, sy mptomatic upper extremity  DVT, sy mptomatic non -fatal PE, incidental PE, and 
all-cause mortalit y, and a composite of symptom atic lower extremity  proximal DVT, 
symptomatic lower extremity  distal DVT, symptomatic upper extremity  DVT, symptomatic non-
fatal PE, and VTE- related deaths.  
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
9
Approved , Date: 5 September [ZIP_CODE].2. Study Design
This is a multicenter, randomized, double -blind, placebo- controlled, parallel- group, superiorit y 
study  comparing the efficacy  and safet y of rivaroxaban with placebo for primary  prophylaxis of 
VTE (defined as DVT and/or PE) in ambulatory  adult men and women, [ADDRESS_569158] a baseline Khorana thromboembolic risk 
score of ≥2, and are judged by [CONTACT_447402] (10 mg orally once daily  for 180 days) or rivaroxaban 
(10 mg orally  once daily  for 180 day s) for thrombo -proph ylaxis based on their clinical status.
The study  consists of 3 periods: a 2-week screening period, a 180-day double -blind treatment 
period with an End -of-T reatment (EOT) visit [for subjects who permanently  stop study  drug ], and 
a 30-day post-treatment follow -up period with a Day 210/End -of-S tudy (EOS) visit. The duration 
of participation in the study  for each subject is approximately 32 weeks.
A target of approximately  700 subjects will be randomly  assigned into the study  in a 1:1 ratio to 1 
of 2 treatment groups (rivaroxaban 10 mg qd and placebo) with approximately  [ADDRESS_569159] discontinuation rate. In addition, subjects will be stratified at 
randomization by [CONTACT_44847] (APC or non-APC) such that approximately  25% of the subjects 
randomly  assigned are those with APC. 
Randomized subjects will continue with their recommended systemic cancer therapy  (SCT) 
during the study period and will be examined by [CONTACT_447403] y (CU) at every 
8-week intervals. Subjects permanently  discontinuing the study  drug will be required to have a 
CU performed within [ADDRESS_569160] dose of study  drug. 
Figure 1: Schematic Overview of the Study
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
10
Approved , Date: 5 September [ZIP_CODE].2.1. Study Drug Discontinuati onandEarly  Withdrawal from Double -Blind 
Period 
As per the protocol (Section 10.2.2), if a subject permanentl y discontinued study  drug before the 
Day 180visit/End of double -blind (EODB )period, this would not result in automatic permanent 
withdrawal of the subject from the study .Subjects areencouraged to make every  effort to 
continue participation in the study and complete the schedule subsequent study  visits until the 
planned end of their study  double -blind duration (Day  180/EODB). Alloutcomes/events data 
(VTE, vital status (alive/dead), MI, stroke, and other thrombosis events) and safety  data 
(including bleeding events) arecollected. If a subject permanently  discontinued study  drug prior 
to Day [ADDRESS_569161] is considered as having ‘completed the double -blind period’ (that is, participated in the 
study  up to the Day 180 visit).  
All subjects including those who discontinued prior to Day 180 visit are contact[CONTACT_447404] a Day 210/EOS follow -up assessment.  Any outcome/event data (including vital status) 
reported during this telephone visit iscollected at this Day 210/EOS visit as agreed upon by[CONTACT_447405].  In the event a subject withdr ew consent or islost-to-follow up, the 
vital status data areobtained through public information (death and other registries) per local 
guidelines and as allowed by  [CONTACT_447406]. 
1.3. Statistical Hy potheses for Study Objectives
The primary  hypothesis ofthis study  is that prophy lactic treatment with rivaroxaban administered 
at a dose of 10 mg once daily  for up to 6 months will be superior to placebo in reducing the risk 
of objectively  confirmed symptomatic lower extremity  proximal DVT, asymptomatic lower
extremity  proximal DVT, symptomatic lower extremity  distal DVT, symptomatic upper extremity 
DVT, symptomatic non-fatal PE, incidental PE, orVTE -related death in ambulatory  adult 
subjects with various cancer types receiving systemic cancer therap y who areat high risk of 
developi[INVESTIGATOR_007] a VTE.
1.4. Sample Size Justification
This is a 6-month fixed duration study  to demonstrate the superiority  of rivaroxaban compared 
with placebo in the ambulatory  cancer subjects undergoing systemic cancer therap y.  Sample size 
deter mination is provided in the protocol Section 11.2 and described below:
Estimates for VTE events in this population vary but point out to a significant benefit (or, 
reduction in events) over placebo when treated with anticoagulant therapy . Pera recent review of 
the VTE prophy laxis studies in cancer subjects by [CONTACT_447407](protocol ref 20 -22), most RCTs 
on solid tumors have reported relative risk reductions (RRRs) anywhere between 50% and 64%. 
The duration of the earlier primary  prophylaxis studies was generally  between 3 to 4 months, in 
conjunction with initiation of systemic anticancer therapy . The basis for predictive events is 
derived from the Vienna CATS group, which utilized the Khorana thromboembolic risk score, 
and followed 819 ambulatory  cancer subjects for symptomatic VTE as an endpoint. In a Kaplan -
Meier analysis, the cumulative probability  of VTE after 6 months: Khorana thromboembolic risk 
score ≥ 3, 17.7% (95% CI: 11.0%- 27.8%, N= 93), and 9.6% (95% CI: 6.2%- 14.7%, N=221) in 
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
11
Approved , Date: [ADDRESS_569162] 12% in subjects with a Khorana thromboembolic 
risk score of >2 is reasonable. The adjudication of objectivel y confirmed asymptomatic DVT and 
PE is estimated to add an additional 5%- 10 % to the primary  efficacy  composite endpoint. 
Based on the above information and recommendations from the Cancer Associated Thrombosis 
Advisory  Council, the sponsor planned the duration of the thrombopro phylaxis treatment in the 
multiple malignancy study  up to [ADDRESS_569163]. Assuming a cumulative incidence rate of 14.5% for the primary 
composite events in the placebo group and 6.0% cumulative incidence rate in the rivaroxaban 
treatment group, a total sample of about 700 randomized subjects (350 per treatment group) will 
be required to demonstrate approximately  60% relative risk reduction (RRR) in the primary  
efficacy  composite endpoint with a 2-sided Type 1 error rate of 5% and >90% statistical power 
(calculation performed by  [CONTACT_447408] 6.3 software) assuming a 20% discontinuation rate. Towards th e 
end of the enrollment phase, approximately [ADDRESS_569164] discontinuation rate. In addition, this sample size will allow for 80% 
statistical power in each stratum (APC or non-APC) for slightl y larger differences in incidence 
rates between the two randomized treatment groups to be statistically  significant.
Essentially , the above overall sample size estimate is calculated based on the following 
assumptions:
 Effect size: absolute difference in event rates = 8.5%, RRR = 58.6%
oPrimary  efficacy  composite endpoint event rate in the placebo arm: 14.5%
oPrimary  efficacy  composite endpoint event rate in the r ivaroxaban arm: 6%
Power: >90%
Overall α level: 5%, 2 -sided
Probability  of droppi[INVESTIGATOR_87020] : 20%
Duration of enrollment period: 12 months
Duration of stud y: 6 months (fixed for each randomized subject)
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
12
Approved , Date: 5 September [ZIP_CODE].5. Randomization and Blindi ng
A centralized randomization strategy  will be implemented in this study . Subjects will be 
randomly  assigned in a 1:[ADDRESS_569165] -randomization schedule prepared by [CONTACT_447409] . The randomization will be stratified by [CONTACT_44847] (Advanced Pancreatic 
Cancer [APC] or non -APC) such that up to approximately  25% of the subjects randomly  assigned 
are those with APC. Using the randomization schedule, the IWRS will assign treatment. The 
IWRS will also provide the number of the study  drug bottle to be dispensed for each randoml y 
assigned subject on Day 1 and at each visit (except Day 180/E nd-of-T reatment ) during the 
double -blind treatment period. The requestor must use his or her own user identification (ID) and 
personal identification number (PIN) when contact[CONTACT_447410]. Based on these randomization 
codes, the study  drug will be packaged and labeled in a manner that maintains the double -blinded 
nature of this study .
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (ie, events that contribute to the 
primary  and secondary  outcome or treatment allocation) will be handled with special care to 
ensure that the integrit y of the blind is maintained and the potential for bias is minimized. This 
can include making special provisions, such as segregating the data in question from view by [CONTACT_4520], clinical team, or others as appropriate until the time of database lock and 
unblinding.
Pancreatic cancer subjects are at a higher risk to develop VTE (VTE Khorana risk score ≥2).  
These subjects are also more likely to discontinue early from the study .Therefore, higher than 
planned ( 25%) number of pan creatic subjects were allowed for enrollment into this study .
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
13
Approved , Date: 5 September [ZIP_CODE]. GENERA L ANAL YSIS DEF INITIONS
2.1. Visit Windows
Data collected in the study  from randomization through End -of-Double- Blind (EODB) will be re-
assigned to visit windows based on the actual date of assessment (only  for theECOG 
performance status evaluation, laboratory  and vital signs data) . 
The reference day is Study  Day1 which will correspond to the randomization day.  The relative 
day will be determined relative to Study  Day  1.
The visit windows are based on the scheduled clinic visits (see Time & Events Schedule in 
protocol) and are defined below:
Period Visit WindowTime Interval sa
for
Visit WindowTarget Dayafor
Visit Window
Screening/R andom ization Baseline ≤1 1
Double -Blind Period Week 8 >1 to 84 56
Week 16 85to 146 112
          Day 180 /EODBb≥147 180
aBased on actual study day of assessment; b = End of Double -Blind Period .  No lab or vital signs data 
were collected at the Day 210 Follow -Up/End -of-Study visit
If more than one assessment falls in the same visit window, the one closest to the target date will 
be used in summary  tables.   In case of a tie (2 or more assessment which are equidistant), the 
latter assessment will be used.
2.2. Baseline
Baseline value is defined as the last observation prior to and including Day  1.
2.3. Pooling A lgorithm for A nalysis Centers
No pooling of centers (with vary ing number of randomized subjects) will be done.
2.4. Analysis Populations 
2.4.1. Intent -to-Treat (ITT) Population
This analy sis population consists of all randomized subjects.  
2.4.2. Per-Protocol (PP) Population
This population is a subset of the ITT population. Subjects with predefined major protocol 
deviations will be excluded from the ITTpopulation. 
The predefined protocol deviations (based on major deviations) employ ed to define the PP 
population are :
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
14
Approved , Date: 5 September 2018Randomized without informed consent (entered study  but inclusion criterion #12 not met)
Received wrong treatment (deviation recorded to be received wr ong treatment or incorrect 
dose)
Randomized but not treated  
Randomized but did not satisfy  the key study entry criteria (inclusion criteria not 
met/exclusion criteria met) 
oInclusion Criteria
#1 Ambulatory men and women ≥18 years of age
#[ADDRESS_569166] a Khorana thromboembolic risk score ≥2
oExclusion Criteria
#[ADDRESS_569167] has diagnosis of primary  brain tumors
#[ADDRESS_569168] has known history of brain metastases
#[ADDRESS_569169] has bleeding diathesis, hemorrhagic lesions, active bleeding and 
other conditions wi th a high risk for bleeding
#[ADDRESS_569170] has hematologic malignancies with the exception of lymphoma
#[ADDRESS_569171] has evidence of VTE on screening Compression Ultrasound or 
incidental VTE identified on spi[INVESTIGATOR_447394] y scans ordered  
primarily  for staging or restaging of malignancy  ≤30 days prior to 
randomization
All protocol deviations, including the deviations listed above will be examined and reviewed from 
a medical perspective prior to End -of-Study /database lock in a blinded fashion and subjects wi ll 
be flagged accordingly  in the final anal ysis database.
2.4.3. Safety Population : 
This population is a subset of the ITT population, consisting of allrandomized subjects who 
receive at least one dose of study  drug.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
15
Approved , Date: 5 September [ZIP_CODE].5. Definition of Study Dates and Observation Period End Dates
The study  dates and period end dates will be used to define the time period for data included in 
the analysis of efficacy  and safety  endpoints for the different observation periods (defined in 
Section 2.6).  
Study Day 1 d ate:the date of randomization of the subject.
End-of-Study (EOS) : the date of the last study -related procedure for the subject (EOS is defined 
as last assessment day during the study , including the Day 210/Post -Treatment Follow Up visit) 
and is defined as the minimum (last assessment day  during the study , death date).
Double -Blind period start date will be the date of randomization.  
Double -Blind period end date will be defined as the completion/ early withdrawal date (date of 
completion or earl y withdrawal [any reason including death] from the double -blind period ).
Up-to-Day 180 observation period end date will be defined as follows;
oDay 180/EODB completion date ( for subjects who completed the double -blind p eriod ) or
oDeath date (subjects who died during thedouble -blind period [DB reason =death] or 
during anytime from randomization through Day  180[died post withdrawal from DBbut 
before Day  180/EODB vis it) or
oMaximum (double -blind withdrawal date, randomization date + 180 days) for subjects 
who withdrew early from the double -blind period [any reason other than death] and had 
not died during the time fro m randomization through Day  [ADDRESS_569172] dose date: the date on which the first dose of study  drug is taken by [CONTACT_423]. If missing 
or partial for a subject who takes study  drug, the first dose date is set to the randomization date. 
Last dose date: the date on which the last dose of study  drug is taken by [CONTACT_423] (dose end 
date). If the dose end date is missing or partial for a subject who takes study  drug, the last dose 
date is set as follows 
Maximum (Minimum (discontinuation date in the double -blind period [including death 
date during double -blind period] , last visit date when drug is dispensed + number of pi[INVESTIGATOR_447395] -number of pi[INVESTIGATOR_447396]), imputed partial last dose date, 
exposure start date of last record ))
oImputation rule forpartial dates :  If only the day is missing, then dayimputed to 
the last day of that month.  If day and month are missing, the date will be imputed 
to the start date if year is the same, else imputed to January  1st.
The last dose date will not be later than the double -blind period end date.  The last dose date will 
not be before the first dose date and if a subject has not taken any study  drug, the last study  drug 
date will be set tomissing.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
16
Approved , Date: [ADDRESS_569173] Dose observation periods .  An observation period refers to a 
time window.  Analy ses of primary  and secondary  efficacy  as well as safety  endpoints will 
include data within a specified observation period.  The primary  efficacy  endpoint analy sis will be 
performed for more than one observation period as shown in the table below .
Up-to-Day 180 observation period: Primary  efficacy  composite endpoint analy ses (including 
supportive and sensitivity  analy ses described in Sections 5.2.3 and 5.2.5 respectivel y) and
secondary  efficacy  endpoints analy ses.
On-Treatment observation period:  Primary  efficacy  composi te endpoint supportive analy sis. 
Primary  and secondary  safet y analyses.
Post-Randomization and Post-First Dose observation periods: Primary  efficacy  composite 
endpoint supportive analy ses.
Analysis of Efficacy Endpoints (Refer to Section s5.2, 0for details ) 
Analysis Population: ITT
Endpoint Observation 
Period (s)Endpoint Observation Period
Prim aryEfficacy Composite 
Endpoint
Time to the first occurrence of 
objectively confirmed 
symptomatic low er extremity 
proximal DVT, asymptomatic 
lower extremity proximal 
DVT, symptomatic lower 
extremity distal DVT, 
symptomatic upper extremity 
DVT, symptomatic non -fatal 
PE, incidental PE, or VTE -
related deathPrim ary
Up-to-Day [ADDRESS_569174] occurrence of 
objectively confirmed 
symptomatic VTE events 
(symptomatic lower 
extremity proximal DVT, 
symptomatic low er extremity 
distal DVT, symptomatic 
upper extremity DVT, or 
symptomatic non -fatal PE) or 
VTE -related deaths
2.Time to all -cause mortality
Additional Secondary
EndpointsKey Secondary & 
Additio nal 
Secondary
Up-to-Day 180
Safety Endpoints (Refer to Section 6.0 for details )
Analysis Population: Safety
Prim ary Endpoint
Time to the first occurrence of 
objectively confirmed ISTH 
major bleeding eventPrim ary
On-TreatmentSecondary Safety Endpoints
On-Treatment
Time to first occurrence of:
1.Clinically relevant non -major 
bleeding
2.Minor bleeding
3.Com posite bleeding (major, 
clinically non -major and 
minor )Secondary
On-Treatment
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
17
Approved , Date: 5 September [ZIP_CODE].6.1. Up-to-Day-180 Observation Period
This observation period includes data from randomization to Up-to-Day 180 end date (defined in 
Section 2.5 ).
Event: All efficacy  events (with respect to deaths, VTE-related deaths arecounted as eventsfor 
primary efficacy endpoint.  For the secondary efficacy endpoints, all-cause deaths are counted as 
events )that occurred from randomization through the Up-to-Day 180 end date (Section 2.5 ) will 
be included in the analy sis of this observation period. 
Event time -The time to event is defined as the time from randomization to the time of the
firstevent during this observation period. 
Censoring: Subjects who did not experience an event during this observation period will be 
censored at the last day  of their complete assessment for stud y outcomes.
Subjects who died during this observation period will be censored as of their death date for 
endpoint analyses not related to death . 
Censoring time -The time to censoring is defined as thetime from randomizat ion to the
minimum of (last day of their complete assessment for study  outcomes during the double -
blind period [double -blind completion/withdrawal], death date [non VTE- related deaths 
for primary  efficacy  composite endpoint] ).
2.6.2. On-Treatment Observation Period
This observation period includes data from theday of thefirst dose of study drug to [ADDRESS_569175] dose of the study drug, inclusively (dose date sdefined in Section 2.5).  
All randomized subjects will be included in the On- Treatment observation period.  A conservative 
approach will be used for subjects who were randomized but never dosed to include any event 
that may  occur even if the subject did not take study  drug .  This i s defined to include VTE -related 
events that occur during the study  even if the subject had not taken study  drug.Only those events 
that occur prior to the double -blind period end date will be included in the on-treatment 
observation period.
Event: All efficacy and safet y events (with respect to deaths, VTE-related deaths arecounted as 
eventsfor primary efficacy composite endpoint .  For Bleeding related deaths , major bleeding is
counted asevent sfor the primary safety endpoint )that occurred from the date of first dose of 
study  drug up to the last dose of study  drug+2 days will be included in the analysis of the On-
Treatment observation period.
Event time -The time to event is defined as the time from first dose date to the time of the 
first event during this observation period.
oFor randomized subjects but never dosed : The time to event will be defined as the 
time from randomization to the time of the event during the time in study .This 
imputation rule will be applied only for the ITT population.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
18
Approved , Date: 5 September 2018Censoring: Subjects who do not experience an event during this observation period will be 
censored .  
Subjects who died during this observation period will be censored as of their death date for 
endpoint anal ysis not related to death .
Censoring time -The time to censoring is defined as the time from first dose date to the 
minimum (earliest) of (last dose date+2 day s,death date ).
oFor randomized subjects but never dosed the time to censoring will be defined as 
the time from randomization to the minimum of (last day of their complete 
assessment for study  outcomes during the double -blind period [double -blind 
completion/withdrawal] , death date [non VTE-related deaths for primary  efficacy 
composite endpoint ]).
2.6.3. Post -Randomization Observation Period
This observation period includes all data from randomization t oDay 210/EOS .
Specificall y, this observation period will include all events that have occurred after randomization 
through Day 210/EOS inclusive of all events after completion of double -blind period/Day  [ADDRESS_569176] had withdrew early from the 
double -blind period through Day  210.
Event: All efficacy  events (with respect to deaths, VTE-related deaths arecounted as eventsfor 
primary efficacy composite endpoint )that occurred from the date of randomization up to the Day 
210/E nd-of-S tudy [EOS ](defined in Section 2.5 ) will be included in the analysis of the Post-
Randomization observation period. 
Event time -The time to event is defined as the time from randomization to the time of the 
first event during this observation period.  
Censoring: Subjects who do not experience an event during this observation period will be 
censored.  
Subjects who died during this observation period will be censored as of their death date for 
endpoint anal ysis not related to death .
Censoring time -The time to censoring will be time from randomization to the minimum 
of (last contact [CONTACT_568] [up to and including the Day 210= EOS date define din Section 2.5 ], 
death date [non VTE-related deaths] ).
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
19
Approved , Date: [ADDRESS_569177] dose of study  drug toDay 210/EOS .
Specificall y, this observation period will include all events that have occurred after first dose 
through Day 210 inclusive of all events after double -blind period completion /Day  180through 
Day [ADDRESS_569178] dose observation period.
Event: All efficacy  events (with respect to deaths, VTE-related deaths are counted as eventsfor 
primary efficacy composite endpoint )that occurred from the date of first dose up to the Day 
210/End-of-S tudy[EOS ] (Section 2.5 ) will be included in the analysis of the Post-First Dose 
observation period. 
Event time -The time to event is defined as the time from first dose date to the time of the 
first event during this observation period .
oFor randomized subjects but never dosed: The time to event will be defined as the 
time from randomization to the time of the event during the time in study . This 
imputation rule will be applied only for the ITT population.
Censoring: Subjects who do not experience an event during this observation period will be 
censored .  
Subjects who died during this observation period will be censored as of their death date for 
endpoint anal ysis not related to death .
Censoring time -The time to censoring is defined as the time from first dose date to the 
minimum (earliest) of (last contact [CONTACT_568] [up to and including Day 210 visit date = EOS 
date defined in Section 2.5 ],death date [non VTE -related deaths] ) 
oFor randomized subjects but never dosed : The time to censoring will be defined as 
the time from randomization to the minimum of (last contact [CONTACT_568] [up to and 
including Day  210=EOS date, death date [non VTE -related deaths] ).
Examples are illustrated in Figures in the Appendix . 
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
20
Approved , Date: [ADDRESS_569179] ratio (HR) and direction, will be 
assessed in the following subgroups classified at baseline:
Stratification factor: Pancreatic ( APC )or Non-Pancreatic (N on-APC )
Age (18 -<65, 65- <75, ≥ 7 5 years)
Sex (Male ,Female)
Race (White, Black, Asian, Other , Unknown, Not Reported )
Ethnicity  (Hispanic or Latino, not Hispanic or Latino, Unknown , Not Reported )
BMI (<25, 25- <30, 30 -<35, ≥35 kg/m2)
Tumor type (Gastric/GE Junction, L ung, Ly mphoma, Ovarian , and Other [which will 
include all the remaining non -pancreatic cancer t ypes] )
Stage of Disease (I, II, III, IV)based on the TNM classification
Baseline Khorana Score ( 2, 3, 4, and ≥5)
Baseline ECOG score (0 -1, ≥ 2)
Geographic region (North America, Western Europe, Eastern Europe )
oNorth America ([LOCATION_003], Canada), Western Europe (Belgium, [LOCATION_009], German y, 
Italy, [LOCATION_006]), Eastern Europe (Bulgaria, Czech Republic, Russia), South America
(Brazil)
Baseline Creatinine Clearance (30 to < 50, 50 to <80, ≥80 mL /min)
Race and ethnicity  for subjects from [LOCATION_009] will be denoted as ‘Not Reported’ in the subgroup 
analysis as this information is not collected from [LOCATION_009] due to local regulations.
3. INTERIM A NALYSIS A NDINDEPENDENT DATA MONITORING COMM ITTEE 
(IDMC)
No interim efficacy  analysis is planned in this study  and there are no pre-specified stoppi[INVESTIGATOR_447397] . However, an IDMC has been set up for this study  to periodicall y assess the 
safet y of subjects in this study and to evaluate the efficacy  data as necessary  to ensure th at the safety 
of subjects is not compromised. Details of the IDMC roles, responsibilities, and key 
activities/timelines are provided in the IDMC charter.
The programming rules for deriving the analy sis variables and the data tables for the IDMC 
meetings are specified in the data presentation specification document (DPS). Brief description is
included in the A ttachment .
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
21
Approved , Date: [ADDRESS_569180] INFORMA TION
4.1. Demographics and Baseline Characteristics
Summaries of demographic and baseline characteristics, risk f actors and medical history  will also 
be provided b y treatment group. 
Descriptive statistics (such as mean, standard deviation, median, minimum and maximum) will be 
provided for continuous variables such as age (at baseline visit), weight, and height. Coun ts and 
(appropriate) percentages will be provided for categorical variables such as sex and race.
4.2. Disposition Information
The number of subjects included in the analysis populations (ITT, PP and safet y) and number of 
subjects who completed or withdrew from the double -blind period will be summarized by 
[CONTACT_447411] : APC or non -APC .
Summaries of reasons for withdrawal from the double -blind period and permanent 
discontinuation of treatment will be provided b y treatment group. 
Time to study  drug discontinuation will be summarized by [CONTACT_175187] -
Meier method.
Time to early study  discontinuation will also be summarized by [CONTACT_447412] -Meier method.
4.3. Treatment Compliance Based on Exposure
Thefollowing rules will be implemented to determine the compliance based on exposure 
information.
For subjects who died during the double- blind period and for those subjects who permanently 
discontinued their treatment early the compliance will be determine d as:
Days on drug= [(last dose date -first dose date+1) –days of drug interruption]
Total exposure duration = last dose date -first dose date+1
Compliance (%) = [Day s on drug/Total exposure duration]x100 
For all other subjects who completed or withdrew (but had not ended treatment early) from 
double -blind period the compliance will be determined as:
Days on drug= [(last dose date -first dose date+1) –days of drug interruption]
Total exposure duration = double -blind end date -first dose date+1
Compliance (%) = [Day s on drug/Total exposure duration]x100 
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
22
Approved , Date: [ADDRESS_569181] 
dose date, inclusive.  Duration of treatment exposure will be summarized by t reatment group.  
Total t reatme nt duration = last dose date - first dose date + 1.
The total number of temporary  drug interruptions (>3 day s) and reasons for interruptions will also 
be summarized by  [CONTACT_1570].
Duration of double -blind period will also be summarized. Theduration ofdouble -blind period is 
defined as the duration from randomization up to the double -blind period end date.
Duration of Double- Blind period = Double -blind period end date (completers or withdrew
subjects) –randomiza tion date + 1 .
4.5. Systemic Cancer Therapi[INVESTIGATOR_447398] -blind period (those that started 
after randomization and those started before randomization by [CONTACT_447413] -blind 
period) will be summarized by [CONTACT_1570]. The number and percentage of randomized 
subjects, who received systemic cancer therapi[INVESTIGATOR_393239].
Concomitant medications include all medications received at or after the randomization date. 
These will be summarized by [CONTACT_1570], for all randomized subjects, using the Anatomical 
Therapeutic Chemical (ATC) dictionary .
4.6. Study Drug Discontinuation andEarly  Withdrawal from Double -Blind 
Period 
If a subject’s study  treatment must be permanently  discontinued before the end of the double -
blind treatment period, this will not result in automatic withdrawal of the subject from the study 
and theyare encouraged to continue to be followed for efficacy  and safet y outcome until the end 
of thedouble -blind period/Day  180. Data from remaining scheduled visits are collected until the 
subject either completes the double -blind period/Day  180 visit or withdraws earl y from the stud y.
Outcome data for all subjects , those who completed the double -blind period as well as those who 
withdrew early from the double -blind period isalso collected at the Day 210/EOS visit as agreed 
during the informed consent.  Every  effort will be made to follow -up the subject and collect the 
data including vital status. In the event a subject withdrew consent or i s lost -to-follow up, the vital 
status data (dead/alive) will beobtained through public information (death and other registries) 
per local guidelines and as allowed b y local registration.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
23
Approved , Date: 5 September 2018Thus, there are two scen arios as described below:
1. Subject permanentl y discontinues study  treatment but completes the double -blind period 
(i.e. completed the stud y/end of double -blind period)
a.If subject experiences an efficacy  (primary  or secondary ) endpoint event at any time 
during the study  (from randomization through double -blind period completion), then 
the event and corresponding time to the occurrence of the event will be included in 
the anal ysis of primary  efficacy  composite endpoint
b.If a subject has no efficacy  composite endpoint event (primary  or secondary ) during 
the time in study , then this subject will be censored with the time to censoring 
defined as the time from randomization to last day of their complete assessment for 
study  outcomes during the double -blind perio d [double -blind completion] .
2. Subject permanentl y discontinues study  treatment and withdraws early prior to the end of 
the double -blind period (i.e. withdrew from the study  altogether) or dies during the double -
blind period
a.If subject experiences an efficacy  composite endpoint event (primary or secondary , 
including VTE-related deaths) after withdrawing from the study  and the time to the 
occurrence of the event is prior to Day 180, then this event and corresponding time 
to the occurrence of the event will be included in the analy sis of primary  efficacy 
composite endpoint .  If subject dies (allcauses other than VTE -related ) after 
withdrawing from the study  and reported on Day [ADDRESS_569182] does not experience any efficacy  composite endpoint event (primary or 
secondary ) in the study ,then this subject will be censored.  The time to censoring is 
defined as the time from randomization to the minimum of (last day of their 
complete assessment for study outcomes during the double -blind period/Day  180 
[double -blind withdrawal date for those who withdrew], or death date [censored at 
death date for analy sis not related to the specific death endpoint ]). 
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
24
Approved , Date: 5 September [ZIP_CODE]. EFFICA CY
5.1. Analysis Specifications
5.1.1. Level of Signi ficance
All statistical tests will be 2-sided and conducted at 5% significance level unless specified 
otherwise. 
The fixed -sequence step down procedure with a priori ordered hypotheses will be used to control 
the type I error for multiple testing (Section 5.5). If the result of a test in the sequence is not 
significant, the tests in lower hierarchical order will be interpreted as not significant regardless of 
the actual p -value.  All confidence intervals will be estimated at the 95% level.
5.1.2. Data Handling Ru les
The primary  efficacy  and key secondary  endpoint analyses in this study  will be based on the ITT 
analysis population (which includes all randomized subjects) .All safety  endpoints will be 
analyzed based on the safet y analy sis population (which includes all randomized subjects who 
receive at least one dose of study  drug) . 
Time to event analy ses will use censoring rules that apply  to subjects with no primary  efficac y 
outcomes during the specified observation period s, or, to subjects who withdrew from the study , 
or to subjects who die because of reasons other than VTE-related or bleeding , or withdre w 
informed consent before the end of the predefined treatment duration (Section 2.6describes in 
detail all the censoring rules for the differen t observation periods).  
All efforts will be made to collect complete data for all subjects randomized in this study to avoid
missing or partial event dates .  Ifthe event date is not known, the investigators will provide their
best estimate as to when the event occurred based on all the data available for that subject . In the 
extreme scenario where the event date is partial (missing day and month and year available), the 
day will be imputed as the first of the month.
5.2. Primary  Efficacy  Composite Endpoint
The primary  efficacy  outcome variables (objectively  confirmed –CEC Adjudicated ) that will be 
used to define the primary  efficacy  composite endpoint are:  
symptomatic lower extremity  proximal DVT
asymptomatic lower extremity  proximal DVT 
symptomatic lower extremity  distal DVT
symptomatic upper extremity  DVT 
symptomatic non -fatal PE 
incidental PE and 
VTE- related death
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
25
Approved , Date: [ADDRESS_569183] occurrence of 
objectively  confirmed symptomatic lower extremity  proximal DVT, asymptomatic lower 
extremity  proximal DVT, symptomatic lower extremity  distal DVT, symptomatic upper extremity 
DVT, symptomatic non-fatal PE, incidental PE or VTE-related death as adjudicated by [CONTACT_447414] (CEC).
5.2.2. Analysis Methods
The primary  efficacy  composite endpoint analysis will be based on the ‘Up-to-Day 180’ 
observation period for the ITT population with censoring as define d in S ection 2.6.  
The cumulative distribution function of the time to first occurrence of the primary  efficac y 
composite endpoint will be estimated by [CONTACT_8761] -Meier method.  The primary  statistical 
hypothesis will be tested using a log -rank test, stra tified by  [CONTACT_20150] t ype (APC or non -APC).
The estimate of the hazard ratio (HR), RRR (RRR=100*[1- HR] %) and the 95% confidence 
intervals for the treatment effect will be provided based on a stratified Cox proportional hazard 
model (stratif ication factor: APC or non-APC) and including treatment group as a binary 
covariate (i.e., rivaroxaban, placebo).
The cumulative event rate derived from Kaplan -Meier estimate will also be display ed graphicall y 
to evaluate the timing of event occurrence and the consistency  of the treatment effect over time.
[IP_ADDRESS]. Assessment of Proportional Hazards A ssumption
The proportional hazards assumption in the primary  efficacy  time-to-event endpoint analy sis 
based on the Cox -proportional hazard model will be assessed graphically  using 
-log(-log) plots
The goodness of fit testing approach as proposed by [CONTACT_447415] (1986)1,2, a variation 
of a test originally  proposed by  [CONTACT_276193] (1982)3
(Kleinbaum and Klein (2012)4provide detail s on the implementation of this approach).
In the event of non-proportional hazards, alternative approaches will be used that include the 
Peto-Prentice test (Peto and Peto, [ZIP_CODE]; Prentice, [ZIP_CODE])and Fleming -Harrington ([ZIP_CODE]) test
(with parameters for this test defined at p=1 and q=0) .  All tests will be performed with the use of
SAS version 9.4or higher (SAS Institute ). Additional data explorations will be carried out to 
assess the non- proportionality  of hazards between groups.
5.2.3. Supportive Analyses for Primary  Efficacy  Composite Endpoint
To assess the robustness of the conclusion of the primary  analysis, supporting analy ses of the 
primary  efficacy  composite endpoint will be performed based on different observation periods 
and analysis populations as described below with censoring rules def ined in Section 2.6:
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
26
Approved , Date: 5 September 2018Based on the ‘On-Treatment ’observation period forthe ITT population 
Based on the ‘Up-to-Day 180’ observation period forthe PP population
Based on the ‘On-Treatment’ observation period forthe PP population 
Based on the ‘Post -Randomization’ observation period for the ITT popula tion
Based on the ‘Post -First Dose’ observation period for the ITT population 
In all cases, the 2 -sided 95% confidence interval (CI ) for the hazard ratio ( rivaroxaban vs p lacebo) 
will be provided using the stratified Cox proportional hazards model (strati fication factor: APC or 
non-APC) and including treatment group as a binary  covariate (i.e., rivaroxaban, placebo).
The cumulative event rate derived from Kaplan -Meier estimate will also be display ed graphicall y 
to evaluate the timing of event occurrence and the consistency  ofthe treatment effect over time 
and tested using a log -rank test, stratified by  [CONTACT_66850] (APC or non- APC).
Summary of Prim ary Efficacy Com posite Endpoint Analysis Methods
Endpoint Observation Period Analysis 
PopulationMethod 
Primary Efficacy 
Com posite Endpoint
(CEC Adjudicated 
Events)   Prim ary
Up-to-Day [ADDRESS_569184] Dose
Up-to-Day 180
Up-to-Day 180ITT
ITT
PP
PP
ITT
ITT
ITT
ITTPrimary Analysis
Kaplan -Meier Estimates 
(Cumulative event rates and
stratified log -rank test)
Cox-model (HR, 95% CI)
Sensitivity Analysis
1.Include asymptomatic distal DVT
2.Dropout w ith no follow  up –treating
time to discontinuation as being time to 
an event.
Com peting Risk Analysis
Deathsdue to causes other than VTE -
related w ill be a com peting risk event
Gray ’s 2-sampel test 
(Cumulative Incidence Function)
Fine and Gray regression model
5.2.4. Subgroup A nalyses for the Primary  Efficacy  Composite Endpoint
Analy ses of the primary  efficacy  composite endpoint will also be performed to examine the 
consistency  of treatment effect across subgroups listed in Section 2.7.  Homogeneity of treatment 
effect will be evaluated using the same model as described in Section 5.2.2 (stratified Cox 
proportional hazard model with treatment as a covariate). Subgroup analysis will be performed if 
there are at least 30total randomized subjects in each subgroup category . Only descriptive 
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
27
Approved , Date: 5 September 2018summaries will be presented for subgroups with fewer subjects. The subgroup analysis by [CONTACT_447416] ‘Not Report ed’ for subjects from [LOCATION_009] as this information is 
not collected from the sites due to local regulation.
The interaction of treatment with each of the subgroups will be analyzed based a stratified Cox 
proportional hazard model with stratification factor and treatment group with addition al terms for 
subgroup and subgroup- by-treatment interaction .  Further evaluations will be performed to assess 
and explain the nature of the interaction (qualitative or quantitative) if a significant (p value 
<0.10) interact ion is observed .  Significant interactions will be examined using a two-sided Gail-
Simon8test.  Descriptive statistics (n, mean, standard deviation, median, and range) will be 
presented b y treatment groups for each subgroup.
The subgroup analy ses of the primary  efficacy  composite endpoint will be based on the‘Up-to-
Day 180’ observation period for the ITT population with censoring as defined in Section 2.6.
5.2.5. Sensitivity Analyses 
[IP_ADDRESS]. Additional Primary  Efficacy  Composite Endpoint –Include 
Asymptomatic Distal DVT
An additional composite efficacy  endpoint will also be defined to include the occurrences of 
‘asymptomatic lower extremity distal DVT’ .  
Sensitivity  analysis will be performed on the time to the first occurrence of objectively  confirmed 
symptomatic lower extremity  proximal DVT, asymptomatic lower extremity  proximal DVT, 
symptomatic lower extremity  distal DVT, asymptomatic lower extremity  distal DVT,
symptomatic upper extremity  DVT, symptomatic non-fatal PE, incidental PE or VTE-related 
death as adjudicated by [CONTACT_447417] (CEC). This analysis will 
be based on the ITT analysis population for the ‘Up-to-Day 180’ observation period.
Cumulative distribution function of the time to first occurrence will be estimated by [CONTACT_8761]-
Meier method and tested using a log- rank test, stratified by  [CONTACT_20150] t ype (APC or non -APC).
The estimate of the hazard ratio (HR), RRR (RRR=100*[1- HR] %) and the 95% confidence 
intervals for the treatment effect will be provided based on a stratified Cox proportional hazard 
model (stratification factor: APC or non-APC) and including treatment group as a binary 
covariate (i.e., rivaroxaban, placebo).
[IP_ADDRESS]. Sensitivity Analysisfor Primary  Efficacy  Composite Endpoint
In this study , all data regarding occurrence of DVT, PE events and vital status (alive/dead) events 
will be collected for all subjects (completers and early  withdrawal) at the Day  210/follow -up visit.  
Data for the primary  efficacy  composite endpoint will be missing for subjects for whom theDay 
210/follow -up visit is not performed or if the visit was performed but the occurrence of an event 
wasreported asunknown. A conservative approach will be used for subjects who withdrew from 
the double -blind period and did not have an event during the double -blind period.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
28
Approved , Date: 5 September 2018In this approach , subjects who withdrew from the double -blind period for any reason other than 
death andwere censored (i.e. had not experienced any VTE-related primary efficacy  event during 
the double -blind period )and have missing or unknown Day210/follow up status will be 
considered as having a VTE-related event (i.e. not censored) .The time from randomization to 
time of withdrawal will be assumed to bethe time to an occurrence of a VTE-related primar y 
efficacy  composite event (no specific individual component w ill be assigned as the worst case ).
The sensitivity  analysis for the primary  efficacy  composite endpoint will be based on the ‘Up-to-
Day 180’ observation period for the ITT analysis population. For the above sensitivity  analyses, 
the cumulative distribution function of the time to first occurrence will be estimated by [CONTACT_17680] -Meier method and tested using a log-rank test, stratified by [CONTACT_44847] (APC or non-
APC).
The estimate of the hazard ratio (HR), RRR (RRR=100*[1- HR] %) and the 95% confidence 
intervals for the treatment effect will be provided based on a stratified Cox proportional hazard 
model (stratification factor: APC or non-APC) and including treatment group as a binary 
covariate (i.e., rivaroxaba n, placebo).
5.3. Competing Risk A nalysis
Competing risks arise when subjects are at risk of experiencing more than one cause of failure 
(event) and failure due to other causes precludes observing the main cause of interest (i.e. 
censored for primary  efficacy  composite endpoint) . 
The primary  efficacy  composite endpoint i s defined as a composite of objectively  confirmed 
symptomatic lower extremity  proximal DVT, asymptomatic lower extremity  proximal DVT, 
symptomatic lower extremity  distal DVT, symptomatic upper extremity  DVT, symptomatic non-
fatal PE, incidental PE or VTE-related death (adjudicated by [CONTACT_142223]). For this type of outcome (the 
primary  endpoint), a death due to causes other than VTE -related is a competing risk event a nd, as 
such, a patient is no longer at risk of having an y of the events of interest.
To account for competing risks (deaths from causes other than venous thromboembolism related; 
VTE-related deaths areincluded in the primary efficacy composite endpoint ) in the primary 
efficacy  analysis, a cumulative incidence approach will be followed with the use of Gray ’s 
(1988)9two-sample test (two -sided alpha level, 0.05). Hazard ratios and 95% confidence intervals 
will be calculated with the use of the Fine and Gray  (1999)10regression model (with treatment 
group as a factor) . Cumulative incidence functions (defined as the cumulative probability  of 
failure from a specific cause over time) will be estimated separatel y for the two study  groups. 
These analy ses will be based on the ‘Up-to-Day 180’ observation period for the ITT population 
with censoring as defined above in Section 2.6 .
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
29
Approved , Date: 5 September [ZIP_CODE].4. Key Secondary  Endpoints
The key  secondary  efficacy  outcomes (objectively confirmed –CEC Adjudicated )are:
symptomatic VTE events (symptomatic lower extremity  proximal DVT , symptomatic 
lower extremity  distal DVT, symptomatic upper extremity  DVTandsymptomatic non-
fatal PE) or VTE -related deaths 
All-cause mortalit y
5.4.1. Definition
The key secondary  efficacy  endpoints defined based on thekey secondary  efficacy  outcomes 
above are as follows:
Time to first occurrence of objectivel y confirmed symptomatic VTE events (symptomatic 
lower extremity  proximal DVT, symptomatic lower extremity  distal DVT, symptomatic 
upper extremity  DVT, orsymptomat ic non- fatal PE ) andVTE- related deaths 
Time to a ll-cause mortality
5.4.2. Analysis Methods
Analy sis of the key  secondary  efficacy  endpoints will follow the same approach as in the analysis 
of the primary  efficacy  composite endpoint analy sis. The analysis will be based on the‘Up-to-
Day 180’observation period forITT population with censoring as defined above (Section 2.6).
Each of the key  secondary  endpoints will be tested using a log-rank test , stratified by [CONTACT_20150] t ype.
For each of these two key secondar y endpoint analy ses, a Cox proportional hazard model with 
treatment and stratification factor as covariates will be fitted. A point estimate along with 2-sided 
95% CI  for the treatment effect of RRR (RRR=100 x [1 -HR] %) will be provided.
The cumulative event rate derived from Kaplan -Meier estimate will also be display ed graphicall y 
to evaluate the timing of event occurrence and the consistency  of the treatment effect over time.
Summary of Key Secondary Efficacy Endpoint sAnalysis Methods
Endpoint Observation 
PeriodAnalysis 
PopulationMethod 
Key Secondary Endpoints 
1. Composite of symptomatic 
VTE events or VTE -related death
2. All-cause mortality
(CEC Adjudicated Events)Up-to-Day 180 ITTKaplan -Meier Estimates 
(Cumulative event rates and 
stratified log-rank test)
Cox-model (HR, 95% CI)
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
30
Approved , Date: [ADDRESS_569185] 
established. Ifthis is established, then a sequential approach using a closed testing hierarchical 
procedure (to control thefamily -wise type I error rate at alpha at 5%, 2 -sided) will be used to test 
the following two secondary  hypothese s:
symptomatic VTE events + VTE -related deaths
all-cause mortality
Overall Hierarchy of Testing Multiple Hypothesis
Primary Efficacy Composite Endpoint (ITT/Up -to-Day 180)
 Time to first occurrence of symptomatic lower extremity proximal DVT, 
asymptomatic lower extremity proximal DVT, symptomatic lower extremity 
distal DVT, symptomatic upper extremity DVT, symptomatic non-fatal PE, 
incidental PE or VTE -related deathα=0.05

Secondary Efficacy Endpoints (ITT/Up -to-Day 180)
 Time to first o ccurrence of symptomatic VTE events andVTE -related death  α=0.05

 All-cause mortality                                                                            α=0.05
5.6. Additional Secondary Efficacy  Variable(s)
Additional secondary outcomes (objectivel y confirmed – CEC Adjudicated ) are:  
Individual components of the primary  efficacy  composite variable
Confirmed fatal/non -fatal arterial thrombosis event (ATE) ( e.g. MI and stroke) events
(thes ewill include the following events: occurrence of a stroke, MI or any arterial 
thrombosis event )
Confirmed fatal/non -fatal visceral VTE events
Composite of sy mptomatic lower extremity  proximal DVT, asy mptomatic lower extremit y 
proximal DVT, symptomatic lower extremity  distal DVT, symptomatic upper extremity 
DVT, sy mptomatic non -fatal PE, incidental PE and all- cause mortality
Composite of symptomatic lower extremity  proximal DVT, symptomatic lower extremity 
distal DVT, symptomatic upper extremity  DVT, symptomatic non-fatal PE and VTE-
related deaths
Composite of events in the primary  efficacy  composite endpoint, fatal/non -fatal ATE, 
visceral VTE
Composite of symptomatic lower extremity  proximal DVT, symptomatic lower extremity 
distal DVT, symptomatic upper extremity  DVT, symptomatic non-fatal PE and VTE-
related deaths and major bleeding events
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
31
Approved , Date: 5 September [ZIP_CODE].6.1. Definition
Secondary  efficacy  endpoints defined based on the other secondary  outcomes above are as 
follows:
Individual components of the primary  efficacy  composite variable
oTime to first occurrence of sy mptomatic lower extremity  proximal DVT
oTime to first occurrence of as ymptomatic lower extremity  proximal DVT
oTime to first occurrence of sy mptomatic lower extremity distal DVT
oTime to first occurrence of sy mptomatic u pper extremity  DVT
oTime to first occurrence of sy mptomatic non -fatal PE
oTime to first occurrence of incidental PE 
oTime to VTE -related death
In addition to the analy sis of the individual components, concordance between the investigator 
reported events and the CEC adjudicated events will also be presented.
Time to first occurrence of fatal/non -fatal ATE (a composite of occurrence ofMI, stroke
[ischemic infarction with or without hemorrhagic conversion or primary  hemorrhagic 
events –intraparench ymal hemorrhage, subdural hematoma or epi[INVESTIGATOR_110116]] or any 
other ATE recorded on eCRF ) event .
Time to first occurrence of fatal/non -fatal visceral VTE event (include only visceral 
(venous) events recorded on the eCRF) .
Composite endpoint #1: Time to first occurrence of the composite endpoint of 
symptomatic lower extremity  proximal DVT, asymptomatic lower extremity  proximal 
DVT, symptomatic lower extremity  distal DVT, symptomatic upper extremity  DVT, 
symptomatic non-fatal PE, incidental PE and all-cause mortalit y (composite: primary
efficacy composite endpoint event components but including all -cause mortality ).
Composite endpoint #2: Time to first occurrence of the composite of symptomatic lower 
extremity  proximal DVT, symptomatic lower extremity  distal DVT, symptomatic upper 
extremity  DVT, symptomatic non-fatal PE and VTE-related deaths (composite: 
symptomatic events only and VTE -related deaths ).
Composite endpoint #3: Time to first occurrence of the primary  efficacy  composite 
endpoint (symptomatic lower extremity  proximal DVT, asymptomatic lower extremity 
proximal DVT, symptomatic lower extremity  distal DVT, symptomatic upper extremity 
DVT, symptomatic non-fatal PE, incidental PE and VTE- related deaths), fatal/non -fatal 
ATE (composite of MI, stroke or any ATE), and fatal/non -fatal visceral VTE event
(composite: primary efficacy composite endpoint event compone nts, ATE events, and 
visceral VTE events).
Composite endpoint # 4: Time to first occurrence of the composite of symptomatic lower 
extremity  proximal DVT, symptomatic lower extremity  distal DVT, symptomatic upper 
extremity  DVT, symptomatic non-fatal PE, VTE- related deaths, and major bleeding event
(composite: symptomatic events and include major bleeding events for the ITT population 
and up -to-Day 180 observation period ).
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
32
Approved , Date: 5 September [ZIP_CODE].6.2. Analysis Methods
Analy sis of the other secondary  efficacy  endpoints will follow the same approach as in the 
analysis of the primary  efficacy  endpoint analysis. These analy ses will be based on the‘Up-to-
Day 180’ observation period for the ITT population with censoring as defined above 
(Section 2.6).
In addition to be above endpoints, the keysecondary  endpoints (time to symptomatic VTE events 
or VTE-related deaths, all-cause mortality ) will also be analy zedbased on the ‘Up-to-Day 180’
observation period for the ITT population.
The cumulative distribution function of the time to first occurrence of each of these endpoints will 
be estimated by [CONTACT_8761] -Meier method and tested using alog-rank test, stratified by [CONTACT_86093]. In addition, a Cox proportional hazard model with treatment and stratification factor as 
covariates will be fitted. A point estimate along with 2-sided 95% CI for the treatment effect of 
RRR (RRR=100 x [1- HR] %) will be provided.
The cumulative event rate derived from Kaplan -Meier estimate will also be display ed graphicall y 
to evaluate the timing of event occurrence and the consistency  of the treatment effect over time.   
No multiplicity  adjustment will be performed for the anal ysis of these endpoints.
Frequency  summary  (N, %) of the total number of deaths and the primary  cause of death, total 
number of subjects with myocardial infarction (MI), stroke, and other arterial thrombosis (ATE) 
events will also be pr esented for the Up -to-Day 180 observation period.
5.7. End-of-Study  Vital Status Summary
In this study , vital status data (alive/dead) was collected at the Day 210 follow up visit for all 
randomized subjects, except for those who had died during the double -blind period. The Cochran -
Mantel -Haenszel (CMH) test, adjusting for the stratification factor (APC/non -APC) ,for the 
association between the treatment group and each of these endpoints will be performed provided 
there are non- zero entries in each cell of the 2x2 treatment -by-endpoint table.  
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
33
Approved , Date: 5 September [ZIP_CODE]. SAFETY
6.1. Bleeding
The primary  safety  objective of this study  is to assess the major bleeding events as defined by 
[CONTACT_447418] y on Thrombosis and Haemostatis (ISTH)based on the CEC classification 
from the time of first dose to two day s after the last dose of study  drug. 
6.1.1. Bleeding Events Classification
Like efficacy  outcomes, the same independent CEC will adjudicate and classify  bleeding events 
perthe definitions in the CEC Charter.
Bleeding events will be classified as major , clinically  relevant non -major, or minor bleeding using 
theISTHclassification as follows:
Major Bleeding
Major bleeding is defined as clinically  overt bleeding that is associated with:
A reduction in hemoglobin of 2 g/dL or more, or
A transfusion of 2 or more units of packed red blood cells or whole blood, or
Occurrence at a critical site defined as intracranial, intra-spi[INVESTIGATOR_1304], intraocular, pericardial, 
intra-articular, intra- muscular with compartment sy ndrome, retroperitoneal, or
Fatal outcome
Clinically Relevant Non- Major Bleeding
Clinically  relevant non-major bleeding defined as overt bleeding not meeting the criteria for 
major bleeding but associated with:
Medical intervention
Unscheduled contact (visit or telephone call) with a phy sician
Temporary  cessation of study  treatment, or
Discomfort such as pain, or impairment of activities of d aily life
Minor Bleeding
All other overt bleeding epi[INVESTIGATOR_447399]-
major bleeding will be classified as minor bleeding (corresponds to minimal bleeding event
captured on the case record form ).
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
34
Approved , Date: 5 September 2018Imputation Rules for Partial Bleeding Start Dates
If the bleeding start date is a partial date (onl y unknown day )
If only the day is missing, and the month and year are known, the month and year of the 
AE will be compared with the month and y ear of double -blind medication start date. 
oIf the both the month and year of the bleeding event is equal to the month and year 
of double -blind medication start date, then the imputed day will be the start day of 
medication.
oIf the month or the year of the bleeding event is different, then the imputed day 
will be the 1stday of the month.
6.1.2. Primary  Safety Endpoint of Bleeding
The primary  safet y endpoint is ISTH major bleeding as adjudicated b y the CEC .
[IP_ADDRESS]. Definition
The primary  safety  endpoint is defined as the time from the first study  drug to first occurrence of 
ISTH major bleeding events in Section 6.1.1 during the ‘On-Treatment ’observation period
(observation periods defined in Section 2.6 ).
Censoring -subjects who do not experience endpoint events during the ‘On-Treatment ’
observation per iod will be censored at the min imum of (last dose date + 2 , death date) .
[IP_ADDRESS]. Analysis Methods
The primary  safety  endpoint will be analyzed using the same approach as in the primary  efficacy  
endpoint but based on the‘On-Treatment’ observation period for theSafety  population
(randomized and taken at least one dose of the study  drug) with censoring as defined above .
The cumulative distribution function of the time to first occurrence of the primary  safety endpoint 
will be estimated by [CONTACT_8761] -Meier method and tested using a log -rank test, stratified by  [CONTACT_86093].
The estimate of the hazard ratio (HR), RRR (RRR=100*[1- HR] %) and the 95% confidence 
intervals for the treatment effect will be provided based on a stratified Cox proportional hazard 
model (stratification factor: APC or non-APC) and including treatment group as a binary 
covariate (i.e., rivaroxaban, placebo).
Incidence of major bleeding events and primary  location of bleeding will also be summarized for 
each treatment group .
The primary safe ty endpoint will also be summarized for the subgroups defined in Section 2.7.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
35
Approved , Date: [ADDRESS_569186] . Multiple major bleeding events will be analyzed using the recurrent event analysis by 
[CONTACT_34153] -Gill (1982)11method.  The supportive analyses will be performed for the ISTH major 
bleeding endpoint and the clinically  relevant non-major bleeding endpoint and will be based on 
the ‘On-Treatment’ observation perio d for the safet y analysis population. All tests will be 
performed with the use of SAS version 9.4 or higher (SAS®Institute).
6.1.4. Secondary  Safety Endpoints of Bleeding
[IP_ADDRESS]. Definition
Secondary  safet y endpoints of bleeding include time to:
Clinica lly relevant non-major bleeding   
Minorbleeding (corresponds to minimal bleeding)
Any bleeding event (defined as a composite of ISTHmajor, clinically  relevant non-major 
and min orbleeding) 
[IP_ADDRESS]. Analysis Methods
The secondary  safety  endpoints of bleeding will be analyzedusing the same approach as in the 
primary  safety endpoint.  The analy sis will be based on the Safety  population in the ‘On-
Treatment ’observation period with censoring as defined above ( Section 2.6).
Each of the secondary  endpoints will be tested using a log-rank test, stratified by [CONTACT_44847] 
(APC or non- APC). In addition, a Cox proportional hazard model with treatment and stratification 
factor as covariates will be fitted. A point estimate for hazard ratio (rivaroxaban/placebo) along 
with 2 -sided 95% CI for the treatment effect of RRR (RRR=100 x [1- HR] %) will be provided.
The cumulative event rate derived from Kaplan-Meier estimate will also be displayed graphically  to 
evaluate the timing of event occurrence and the consistency of the treatment effect over time.
Summary of Safety Endpoint sAnalysis Methods
Endpoint Observ ation Period Analysis 
PopulationMethod 
Prim ary Endpoint 
ISTH Major bleeding event
Secondary Endpoints
1. Clinically relevant non -major 
bleeding
2. Minor bleeding
3.Com posite bleeding event (major, 
clinically non -major and minor)
(CEC Adjudicated Events)On-Treatment SafetyKaplan -Meier Estimates 
(Cumulative event rates
and log-rank test )
Cox-model (HR, 95% CI)
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
36
Approved , Date: 5 September [ZIP_CODE].2. Adverse Events
The original terms used in the CRFs by [CONTACT_447419] (MedDRA) version 20.0 or higher . 
A treatment -emergent adverse event (TEAE ) is defined as any adverse event that starts between 
the first study  medication administration and the last study  medication administrat ion + [ADDRESS_569187] dose date+2 days will be 
included in all TEAE sum maries, including study (double -blind period) withdrawal and treatment 
discontinuation.   
As per the protocol (Section 12.4), in this study suspected outcome events are excluded from 
AE/SAE collection and reporting, regardless of seriousness or severity . These suspected events 
will be captured on the eCRF as outcome events and will be waived from SAE collection and 
unblinding and exempted from expedited reporting. These events include: symptomatic lower 
extremity  proximal DVT, asymptomatic lower extremity  proximal DVT, symptomatic lower 
extremity  distal DVT , symptomatic upper extremity  DVT, symptomatic non-fatal PE, incidental 
PE, VTE-related death , all-cause mortality , ATE events (e.g., MI, stroke) , visceral VTE , and all 
bleeding events.
The number (%) of subjects who had treatment -emergent adverse events will be summarized by 
[CONTACT_447420] C lass (SOC) and preferred term (PT) for the Safet y anal ysis population .
The number and percentage of subjects experiencing TEAEs will be summarized by [CONTACT_447421] y analysis population , and stratification factor: APC or non -APC .  
In addition, overall summaries of all AEs (all AEs that are reported from start of study  through 
theDay 210/E nd-of-Study ) for the safet y population will also be presented .  Summary table of 
AEby [CONTACT_447422].
Adverse events will also be summarized by [CONTACT_1570], severity , relationship to study 
medication, combined severit y and relationship to study  medication, action taken during 
treatment, and subject outcome. They  will also be presented b y treatment grou p, SOC, and PT.
Differences in the percentages of AEs between the two groups will be summarized and the 95% 
CI for the difference using the normal approximation to binomial distribution will be provided.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
37
Approved , Date: 5 September [ZIP_CODE].2.1. Imputation Rules for Missing A E Dates
A conservative approach will be used to handle the missing dates for adverse events. The rules for 
handling the incomplete AE onset dates will be as follows:
If only the day is missing, and the month and year are known, the month and year of the 
AE will be compared with the month and y ear of double -blind medication start date. 
oIf the both the month and year of the AE is equal to the month and year of double -
blind medication start date, then the imputed day will bethe start day of 
medication.
oIf the month or the year ofthe AE aredifferent, then the imputed day will be th e 1st
day of the month.
If only the month is missing, and day and year are known, the year of the AE will be 
compared with the year of the double- blind medication start date.
oIf the year of the AE is equal to the year of the double -blind medication start date, 
then the imputed month will be the same as the month of the double -blind 
medication. 
oIf the year is different, then the month will be as January .
If both the day and month are missing but year is known, compare the year with the year 
of the double -blind medication start date. 
oIf the year is the same, then impute the AE start date as the same as the first dose 
date.  
oIf the year is different, then impute t he AE start dat e to be January  1.
If the day, month and year are all missing, then the imputed date for the AE will be the 
date of the first dose of study  medication.
After imputation if the AE start date is greater than the AE end date, then the AE start date will be 
set equal to the AE end date.
No imputation will be done for AE end date.
6.2.2. Adverse Events Resulting in Withdrawal from the Study and 
Discontinuation of Treatment :
The number and percentage of subjects who withdrew from thedouble -blind period due to an 
TEA E(TEAE led to withdrawal from the study) will be summarized by [CONTACT_447423]. In addition, TEAEs that led to discontinuation of study  drug (drug withdrawal )
will also be summarized by  [CONTACT_1570].
In addition, overall summaries of all AEs (all AEs that are reported from start of study  through 
the Day  210/End-of- Study ) with action taken of drug withdrawal will also be presented
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
38
Approved , Date: 5 September [ZIP_CODE].2.3. Serious A dverse Events (SA E) and Deaths during the Study :
The number and percentage of serious TEAE and deaths will be summarized by [CONTACT_447424].  
Serious TEAE that led to study  drug discontinuation will be summarized by [CONTACT_447425]. 
In addition, all serious AEs and deaths (all AEs that are reported from start of study  through the 
Day 210/End-of- Study ) will also be summarized.  
6.2.4. Adverse Events of Special Interest 
In addition to the overall AEs summaries, certain AEs that are considered to be Adverse Events of 
Special Inter est (AESI) will be summarized.  The special interest TEAEs for the following groups 
will be summarized:
Suspected severe h ypersensitivity  reaction 
SMQ preferred terms included are: anaphy laxis, angioedema, severe urticaria , 
bronchospasm, idiopathic urticaria, anaph ylactic reaction, anaphy lactic shock, 
anaph ylactoid reaction, and anaph ylacticshock.
Severe skin reactions  
SMQ preferred terms included are: Stevens- Johnson Sy ndrome .
Suspected severe liver injury
SMQ preferred terms included are: drug-induced liver injury , acute hepatic failure, 
hepatic failure, hepatocellular injury , liver injury , mixed liver injury , alanine 
aminotransferase abnormal, alanine aminotransferase increase, aspartate 
aminotransferase abnormal, aspartate aminotransferase increased, blood bilirubin 
increased, blood bilirubin unconjugated increased, hyperbilirubinaemia, and liver 
function test abnormal.
Summaries of the special interest TEAEs will be based on the safet y population.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
39
Approved , Date: 5 September [ZIP_CODE].3. Clinical Laboratory  Tests
Descriptive statistics for each clinical laboratory analyte (collected at baseline and at Week 8, 
Week 16, and EODB will be provided. C hanges from baseline at each post-baseline visit will be 
calculated by [CONTACT_447426] ‘Up-to-Day 180’
observation period. The number of shifts from baseline in the categories of test results (low, 
normal, high) will be summarized by [CONTACT_1570]. A clinical laboratory  test value is 
considered abnormal if it is outside the reference range (provided by [CONTACT_25699] ). Incidences 
of abnormal laboratory  values will be summarized by [CONTACT_447427] -missing baseline and non -missing post -baseline values.
All laboratory  test summaries will be based on the safety population (data from first dose through 
Day 180).  Laboratory  data from the central lab Covance will onl y be included in the summaries.
6.4. Vital Signs and Phy sical Examination Findings
Vital Signs
Descriptive statistics (mean, median, standard deviation, range, and number of observations) for 
blood pressure (systolic and diastolic) and pulse will be provided by [CONTACT_447428] y analysis population . The changes from baseline for vital signs will also be summarized by 
[CONTACT_10635].   
Physical Examinations
Listings of ph ysical examination results will be provided.
All vital signs and physical examination summaries will be based on the safet y population (data 
from first dose through Day  210) .
6.5. Electrocardiogram
N/A
6.6. Other Safety  Parameters
N/A
7. PHA RMA COKINETICS/PHA RMA CODYNAMICS
7.1. Pharmacokinetics
Pharmacokinetics samples collected at Month 2 (Week 8) will be analy zed and descriptive 
statistics (n, mean, standard deviation, median, and rage) for plasma concentrations will be 
provided.  
7.2. Pharmacody namics
N/A
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
40
Approved , Date: 5 September [ZIP_CODE]. BIOMA RKER 
In this study , biomarker samples are collected at screening, month 2 (Week 8), month 4 (Week 
16) and month 6 (EODB).  Biomarker assessments which include D-dimer, soluble P-selectin, 
and Tissue Factor (Factor III) will be summarized as part of the laboratory  data summary .
9. HEA LTH CA RE RESOURCE UTILIZ ATION
The Health Care Resource Utilization (HCRU) data will be collected as part of the endpoint 
assessments for all patients. The HCRU data will be specific to the study  outcom es of DVT, PE, 
or bleeding, including outpatient visits to health care providers (including all specialties) , 
hospi[INVESTIGATOR_059] s(including admittance to intensive care unit),time to first hospi[INVESTIGATOR_059] (DVT, 
PE, bleeding or an AE), length of hospi[INVESTIGATOR_059] (defined as the sum of the duration of days over 
all the hospi[INVESTIGATOR_602]), and use of diagnostic procedures (type of imaging or diagnostic tests 
performed). Descriptive summaries (frequency  counts and mean, median, SD) will be provided 
for the HCRU. All summaries will be presented by [CONTACT_447429] .  
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
41
Approved , Date: 5 September 2018REFERENCES
1. Harrell F. and Lee K. (1986) Proceedings of the Eleventh Annual SASW User’s Group International ,823–828.
2. Harrell F. and Lee K. (1986) Verifying Assumptions of the Cox Proportional Hazards Model.  Proceeding of the 
Eleventh Annual SAS User’s Group International conference, Cary, NC, SAS Institute, Inc.  
3. Schoenfeld D. (1982) Partial residuals for the proportional hazards model. Biometrika, 69, 51 –55
4. Kleinbaum GD and Klein M. (2012) Survival Analysis -A Self -Learning Text, Third Edition. Springer
5. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (w ith Discussion). Journal of the Royal 
Statistical Society, Series A. 1972; 135:185 –206.
6. Prentice RL. Linear rank tests with right censored data. Biometrika. 1978; 65:167 –179.
7. Fleming, TR.; Harrington, DP. Topi[INVESTIGATOR_447400]. New  York: Marcel Dekker; 1984. Evaluation of 
censored survival data test procedures based on single and multi ple statistics; 97 -123.
8. Gail, M. and Simon, R.  Testing for Qualitative Interactions betw een Treatment Effects and Patient Subsets.  
Biometrics 1985; 41(2): 361 -372.
9. Gray  R.J. (1988) A class of k -sample tests for comparing the cumulative incidence of a com peting risk, Annals 
of Statistics, 6, 1141 -1154
10. Fine J. and Gray R. (1999) A proportional hazards model for the subpopulation of a competing risk, Journal of 
American Statistical Association, 94, 496 -509
11. Andersen, P. K. and Gill, R. D. (1982), “Cox’s Regre ssion Model Counting Process: A Large Sample 
Study,” Annals of Statistics , 10, 1100 –1120.
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
42
Approved , Date: 5 September 2018ATTACHMENT : EXAMPLES OBSERVA TION PERIOD A ND EVENT/CEN SORING TIME 
The different observation periods and the time intervals within which study  data will be included are shown in the figures be low.
Figure 1: Up-to-Day 180 observation period
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
43
Approved , Date: 5 September 2018Figure 2: On -Treatment observation period
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
44
Approved , Date: 5 September 2018Figure 3: Post- Randomization observation period
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
45
Approved , Date: 5 September 2018Figure 4: Post-Randomization observation period
[STUDY_ID_REMOVED]
BAY59 -7939/JNJ39039039STM4001   (Rivaroxaban )                                            Statistical Analysis Plan STM4001
46
Approved , Date: 5 September 2018ATTACHMENT : IDMC DATA PRESENTA TION SPECIFICA TION
The study  SAP is used as the IDMC SAP however some of the rules for imputation times and 
missing dates due to data cutoffs were applied to generate the tables for the DMC meetings .
As per the IDMC Charter, three meetings were planned to be conducted for safet y data andkey 
efficacy  data reviews .The IDMC meetings are scheduled at the availability  of 25 % data (that is, 
when 25% of total planned subjects are randomized into the study  and complete at least 30 days 
on study ).  Each of subsequent 2 meetings coincide with the enrollment of 50% and 75% of the 
planned subjects respectively  who have been randomized and completed at least 30 days of study 
follow -up.  An addition ad hoc review (fourth IDMC safet y review meeting) was planned at the 
end of enrollment when 100% subje cts are randomized.  
Appropriate database w asprovided to IDMC statistical support group in accordance with the DMC 
Charter and established timeframes for each meeting.
For the fourth DMC meeting, sym ptomatic distal DVT was included in the primary effic acy 
composite endpoint in accordance with the amended protocol.  
Rules
Analy sis phase end date: min (death date, rand date+ 183, cutoff date)
Treatment end date imputed as: min (rand date+183, cutoff date, analysis phase end date ) for 
ongoing subjects.
CNSR: the censor flag = 0 if event and censor flag = 1 if censor (no event)
Event date:
ADT: the date of event up to the time subject was in the study.  That is, up to the subject’s 
completion/withdrawal date (the Day 180 end date not defined for DMC ).
Censor date:
Up-to-Day 180 observation period:  
ADT for censored subjects = min ( death date, rand date+183, cutoff date) 
On-Treatment observation period:
ADT for censored subjects = min ( death date, last dose+2), using the imputed TRTEDT
[STUDY_ID_REMOVED]